Cicatrix Clinical Trial
Official title:
A Trial to Investigate the Accelerated Wound Healing and Antiscarring Potential, Safety, Toleration and Systemic Exposure of Intradermal RN1001 (Avotermin) in Male and Female Subjects Aged 60 Years and Over.
An exploratory Phase-II trial with intradermal RN1001 (Avotermin) to investigate scar prevention and reduction and acceleration of healing. The trial has an additional objective to evaluate several different scar assessment techniques that can be used in future clinical trials in the prevention and reduction of scarring.
Status | Completed |
Enrollment | 42 |
Est. completion date | June 2003 |
Est. primary completion date | June 2003 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 60 Years and older |
Eligibility |
Inclusion Criteria: - Clinically healthy, male and female subjects aged 60 years and over. All females will be at least 2 years post menopausal. - Weight between 50 and 150kg or a body mass index within the permitted range for their height using Quetelet's index-weight (kg)/height²(m). The permitted index is between 15 - 35 kg/m2. Exclusion Criteria: - Subjects who on direct questioning and physical examination have a history or evidence of hypertrophic or keloid scarring or with tattoos or previous scars in the area to be biopsied. - Subjects with a personal history of a bleeding disorder. - Subjects with a skin disorder that is chronic or currently active and which the investigator considers will adversely affect the healing the acute wounds or involves the areas to be examined in this trial. - Subjects with any clinically significant medical condition that would impair wound healing including renal, hepatic, haematological, neurological or immune disease. - Subjects with a history of clinically significant drug hypersensitivity to lignocaine or allergy to surgical dressings to be used in this trial. - Subjects with any clinically significant abnormality following review of pre trial laboratory data and physical examination (see above). - Subjects who are taking, or have taken, any investigational drugs, long term oral, topical or inhaled corticosteroid therapy, hormone replacement therapy (HRT) or anti-coagulant drugs in the thirty days prior to Day 0. - Subjects who have evidence of drug abuse. - Subjects who are known to have or had serum hepatitis or who are carriers of the hepatitis B surface antigen or hepatitis C antibody. Subjects with previous vaccination against Hepatitis B are not excluded per se. - Subjects who are known to have or had serum hepatitis or who are carriers of the hepatitis B core antibody and who show less than 10 units per litre of Anti-HBs. - Subjects who have previously had a positive result to the test for HIV antibodies, or who admit to belonging to a high-risk group. - In the opinion of the investigator, a subject who is not likely to complete the trial for what ever reason. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
United Kingdom | Renovo CTU | Manchester |
Lead Sponsor | Collaborator |
---|---|
Renovo |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of scar appearance by an independent panel | 6 months | No | |
Secondary | Histological evaluation of wound healing | 3 days | No | |
Secondary | Adverse event occurance | 6 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02645773 -
Early Intervention With Non-ablative Fractional Laser to Reduce Cutaneous Scarring
|
N/A | |
Completed |
NCT02672956 -
Comparison of Different Umbilical Port Entry Techniques in Terms of Cosmetic Results
|
N/A | |
Completed |
NCT00629811 -
Improvement in Scar Appearance Following Injection of Avotermin (Juvista) Into Skin Incisions Made in Healthy Men and Women
|
Phase 2 | |
Completed |
NCT00977951 -
Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03213548 -
Aesthetic and Functional Results of Alar Base Modifications in Rhinoplasty
|
N/A | |
Recruiting |
NCT05377723 -
Abdominal Scar Improvement in Microsurgical Breast Reconstruction
|
N/A | |
Active, not recruiting |
NCT01976260 -
A Pilot Study Testing Fractional Radiofrequency Versus Fractional Photothermolysis for the Treatment of Acne Scars
|
N/A | |
Terminated |
NCT00432328 -
Juvista (Avotermin) in Breast Reduction Surgery Scars
|
Phase 2 | |
Completed |
NCT00594581 -
Anti-Scarring Efficacy and Safety of Intradermal Juvista (Avotermin) in Healthy Males
|
Phase 2 | |
Completed |
NCT00984503 -
Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites
|
Phase 2 | |
Recruiting |
NCT04420442 -
Scar Resection and Reconstruction With Integra and Split Skin Grafts in Patients With Non-Suicidal Self-Inflicted Scars
|
N/A | |
Completed |
NCT02772289 -
Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars
|
Phase 2 | |
Completed |
NCT00430326 -
Juvista (Avotermin) in Scars Following Varicose Vein Removal
|
Phase 2 | |
Completed |
NCT00847925 -
Safety and Efficacy of RN1001(Avotermin) in Healthy Male Subjects
|
Phase 1/Phase 2 | |
Recruiting |
NCT05787171 -
Three Sutures With Different Absorption Rates for Lower Abdominal Incision
|
N/A | |
Completed |
NCT02985151 -
Interventional Study to Evaluate the Appearance of Surgical Scars After Laser Therapy
|
N/A | |
Completed |
NCT02340325 -
FS2 Safety and Tolerability Study in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT00432211 -
Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery.
|
Phase 2 | |
Completed |
NCT00978302 -
Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista)
|
Phase 1 | |
Withdrawn |
NCT04034615 -
The Long-term Effect of Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars
|
Phase 2 |